AbbVie and Gubra A/S, a company specializing in preclinical contract research services and peptide-based drug discovery, have signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development and commercialization activities of GUB014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in develop...